Parallel Advisors’s Celldex Therapeutics CLDX Stock Holding History

Parallel Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.28K	Hold	132	–	–	﹤0.01%	3418
2026 Q2	$4.91K	Sell	132 -32	-20%	-$1.03K	﹤0.01%	3215
2026 Q1	$5.2K	Buy	164 +90	+122%	+$2.45K	﹤0.01%	3016
2025 Q4	$2.01K	Hold	74	–	–	﹤0.01%	3130
2025 Q3	$1.91K	Hold	74	–	–	﹤0.01%	3058
2025 Q2	$1.51K	Sell	74 -859	-92%	-$16.7K	﹤0.01%	3112
2025 Q1	$16.9K	Buy	933 +854	+1,081%	+$19.1K	﹤0.01%	2219
2024 Q4	$2K	Buy	79 +57	+259%	+$1.55K	﹤0.01%	2970
2024 Q3	$748	Hold	22	–	–	﹤0.01%	3096
2024 Q2	$814	Hold	22	–	–	﹤0.01%	3008
2024 Q1	$923	Hold	22	–	–	﹤0.01%	2951
2023 Q4	$873	Hold	22	–	–	﹤0.01%	2967
2023 Q3	$605	Hold	22	–	–	﹤0.01%	3071
2023 Q2	$746	Sell	22 -2	-8%	-$67	﹤0.01%	3004
2023 Q1	$864	Hold	24	–	–	﹤0.01%	2992
2022 Q4	$1.07K	Sell	24 -2	-8%	-$71	﹤0.01%	2881
2022 Q3	$1K	Buy	26 +4	+18%	+$123	﹤0.01%	2866
2022 Q2	$1K	Buy	+22	New	+$639	﹤0.01%	2722

Other funds holding CLDX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Parallel Advisors's CLDX Position: Q3 2026 in Review

Parallel Advisors held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 132 shares worth $4.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3418.

Parallel Advisors first reported a position in CLDX in Q2 2022 and has held it in 18 quarters since. The position peaked at $16.9K in Q1 2025. 56 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Parallel Advisors held 132 shares of Celldex Therapeutics worth $4.28K as of Q3 2026.
Parallel Advisors left its Celldex Therapeutics share count unchanged in Q3 2026.
Celldex Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3418 holding.
Parallel Advisors first reported a position in Celldex Therapeutics in Q2 2022 and has held it in 18 quarters since.
Parallel Advisors's Celldex Therapeutics position peaked at $16.9K in Q1 2025.
56 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.